Literature DB >> 12040510

[Advances in the physiopathology of epileptogenesis: molecular aspects].

J A Armijo1, E M Valdizán, I De Las Cuevas, A Cuadrado.   

Abstract

OBJECTIVE: We review the molecular basis of epileptogenesis and the new perspectives in the treatment of epilepsy. DEVELOPMENT: Epileptogenesis are the molecular and cellular events producing the disordered firing of a subpopulation of neurons resulting in periodic seizures. Epilepsies may be due to genetic and acquired factors. Some idiopathic epilepsies are due to mutant genes coding voltage gated sodium and potassium channels, GABAA receptor chloride channels and nicotinic acetylcholine receptor sodium channels. Genetic defects also produce epilepsy secondary to either neuronal developmental or metabolic abnormalities, and may contribute to acquired epilepsy. Events observed in both animal and human acquired epilepsies are an increase in glutamate levels and NMDA receptor sensitivity, selective lost of pyramidal neurons, mossy fibre sprouting and neosinaptogenesis. There is also a reduction in inhibitory control due to lost of GABAergic interneurons, and a decrease in GABA levels and GABAA receptor sensitivity. Hyperexcitability may be also due to reduction in glial ATPasa activity, increase in astrocytes gap junctions, and decrease in extracellular calcium. Chandelier GABAergic interneuron microlesions and an hyperexcitable thalamus are key in spread of partial seizures. Absences may be caused by cortex hyperexcitability and genetic abnormalities in thalamic voltage gated T calcium channels. Brain stem is key in convulsive seizures. The role of voltage gated potassium, sodium and calcium channels, and GABAergic and glutamatergic neurotransmission in epileptogenesis and treatment of epilepsies are revised. The role of other neurotransmitters and neuromodulators, second messengers, and immediate early genes and neurotrophins are also commented.
CONCLUSION: Understanding the molecular basis of epileptogenesis should lead to the rational design of drugs both to prevent the development of epilepsy, and minimize hyperexcitability which may be the result of a genetic or acquired disorder.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12040510

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  5 in total

Review 1.  Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

Review 2.  Production and organization of neocortical interneurons.

Authors:  Khadeejah T Sultan; Keith N Brown; Song-Hai Shi
Journal:  Front Cell Neurosci       Date:  2013-11-21       Impact factor: 5.505

3.  Caspase 3 involves in neuroplasticity, microglial activation and neurogenesis in the mice hippocampus after intracerebral injection of kainic acid.

Authors:  Tsai-Teng Tzeng; Huey-Jen Tsay; Luping Chang; Chia-Lin Hsu; Tzu-Hsuan Lai; Fong-Lee Huang; Young-Ji Shiao
Journal:  J Biomed Sci       Date:  2013-12-06       Impact factor: 8.410

4.  Benzodiazepine partially reverses tonic-clonic seizures induced by thiocolchicoside.

Authors:  D S Leitão; A R Andrade; N C L Medeiros; M F C Martins; L O Ferreira; V C Santos; A O Hamoy; L A L Barbas; N A Muto; V Jóia de Mello; D C F Lopes; M Hamoy
Journal:  Braz J Med Biol Res       Date:  2022-02-28       Impact factor: 2.590

5.  SOX6 controls dorsal progenitor identity and interneuron diversity during neocortical development.

Authors:  Eiman Azim; Denis Jabaudon; Ryann M Fame; Jeffrey D Macklis
Journal:  Nat Neurosci       Date:  2009-08-05       Impact factor: 24.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.